Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167346 | 0.85 | FAAH (0.48) | FAAHALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL14937617 | 0.82 | PPID (0.46) | FAAHALDH1A1KDM4EKLK7SMN1; SMN2 | |
| SCHEMBL27647927 | 0.81 | GPR119 (0.49) | FAAH | |
| SCHEMBL14950184 | 0.80 | MAPT (0.48) | FAAHALDH1A1SMN1; SMN2POLBRAB9A | |
| SCHEMBL14946891 | 0.80 | FAAH (0.48) | FAAHALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL10645106 | 0.79 | FAAH (0.56) | FAAHALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL14950180 | 0.77 | MAPT (0.48) | FAAHSMN1; SMN2POLBNPC1MAPT | |
| SCHEMBL6255349 | 0.77 | SMN1; SMN2 (0.46) | FAAHALDH1A1KDM4EKLK7SMN1; SMN2 | |
| SCHEMBL2181000 | 0.76 | FAAH (0.64) | FAAHSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL4418553 | 0.76 | ALDH1A1 (0.59) | FAAHALDH1A1KDM4EKLK7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216227-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2017-08-03 | — | — | US | claimed |
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-03-12 | — | — | US | claimed |
| US-20120277289-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | MARINA BIOTECH, INC. (US) | 2012-11-01 | — | — | US | claimed |
| JP-2001527506-A | — | — | 2001-12-25 | — | — | JP | claimed |
| EP-0626969-B1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2000-05-24 | — | — | EP | claimed |
| US-5648373-A | CoA-IT and PAF inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-15 | — | — | US | claimed |
| EP-0626969-A4 | CoA-IT AND PAF INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-04-19 | — | — | EP | claimed |
| EP-0626969-A1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-07 | — | — | EP | claimed |
| WO-1993016674-A1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | claimed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| EP-0626969-B1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2000-05-24 | — | — | EP | disclosed |
| US-5663053-A | COENZYME A TRANSACYLASE FOR SCREENING | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5648373-A | CoA-IT and PAF inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0626969-A4 | CoA-IT AND PAF INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0626969-A1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993016674-A1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277289-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | XPA, NPPA, LNPEP | FAAH 2480/4885ALDH1A1 2634/4885KDM4E 4523/4885 |
| US-20170216227-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | LNPEP, LDLR, XPA | FAAH 2994/4885ALDH1A1 3348/4885KDM4E 4176/4885 |
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | LNPEP, LDLR, XPA | FAAH 2994/4885ALDH1A1 3348/4885KDM4E 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.